EBV (Epstein-Barr virus)-targeted therapy is limited by efficient agents inducing lytic cycle in cancer cells. Here they report a transcriptional activator incorporated into lipid nanoparticles that could specifically activate endogenous BZLF1 and induce lytic reactivation in EBV-positive cancer cells thereby suppress tumor progression.
All Keywords
【저자키워드】 Targeted therapies, Cancer models, Tumour virus infections,
【저자키워드】 Targeted therapies, Cancer models, Tumour virus infections,